Corcept Therapeutics. has filed a patent for methods and compositions to treat non-ACTH-secreting pancreatic tumors. The patent claims the use of an antimicrotubule agent, such as a vinca alkaloid or taxane, along with a nonsteroidal selective glucocorticoid receptor modulator (SGRM) to reduce tumor load. The SGRM can have a fused azadecalin structure, a heteroaryl-ketone fused azadecalin structure, or an octahydro fused azadecalin structure. GlobalData’s report on Corcept Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Corcept Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Corcept Therapeutics's grant share as of September 2023 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
The patent filed is for a method of treating non-acth-secreting pancreatic tumors using a specific combination of drugs
A recently filed patent (Publication Number: US20230285361A1) describes a method for treating non-ACTH-secreting pancreatic tumors. The method involves administering an antimicrotubule agent, specifically a vinca alkaloid or a taxane, along with a nonsteroidal selective glucocorticoid receptor modulator (SGRM) to reduce the tumor load. The SGRM is administered at a dosage ranging from about 20 milligrams per day (mg/day) to about 1000 mg/day.
The patent claims specify that the non-ACTH-secreting pancreatic tumor can be an exocrine pancreatic tumor. The antimicrotubule agent can be a vinca alkaloid such as vinorelbine, vincristine, vindesine, vinblastine, vincaleukoblastine, or a combination thereof. Alternatively, it can be a taxane such as docetaxel, paclitaxel, nanoparticle albumin-bound paclitaxel (nab-paclitaxel), docosahexaenoic acid bound-paclitaxel (DHA-paclitaxel), polyglutamate bound-paclitaxel (PG-paclitaxel), ANG105 (Angiopep-2 bound to three molecules of paclitaxel), paclitaxel-EC-1 (paclitaxel bound to the erbB2-recognizing peptide EC-1), glucose-conjugated paclitaxel, or a combination thereof.
The patent claims also mention that the SGRM can be selected from nab-paclitaxel, paclitaxel, docetaxel, vinorelbine, vincristine, and vinblastine. Additionally, the SGRM can be a compound with a fused azadecalin structure, a heteroaryl-ketone fused azadecalin structure, or an octahydro fused azadecalin structure. The specific chemical formulas for these structures are provided in the patent claims.
Furthermore, the patent claims state that the SGRM can be administered intermittently, indicating that the treatment may not be continuous but rather given at specific intervals.
In summary, the patent describes a method for treating non-ACTH-secreting pancreatic tumors by combining an antimicrotubule agent (vinca alkaloid or taxane) with a nonsteroidal selective glucocorticoid receptor modulator (SGRM). The dosage of the SGRM ranges from about 20 mg/day to about 1000 mg/day. The treatment can be used for exocrine pancreatic tumors and involves intermittent administration of the SGRM.
To know more about GlobalData’s detailed insights on Corcept Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
